Copyright
©2014 Baishideng Publishing Group Inc.
World J Transplant. Jun 24, 2014; 4(2): 133-140
Published online Jun 24, 2014. doi: 10.5500/wjt.v4.i2.133
Published online Jun 24, 2014. doi: 10.5500/wjt.v4.i2.133
Figure 1 Box plots of serum transforming growth factor-β (A) and serum Hyaluronic acid (B) in patients under calcineurin inhibitors or everolimus regime.
TGF-β: Transforming growth factor-β; CNI: Calcineurin inhibitors.
- Citation: Fernández-Yunquera A, Ripoll C, Bañares R, Puerto M, Rincón D, Yepes I, Catalina V, Salcedo M. Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients. World J Transplant 2014; 4(2): 133-140
- URL: https://www.wjgnet.com/2220-3230/full/v4/i2/133.htm
- DOI: https://dx.doi.org/10.5500/wjt.v4.i2.133